Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ONCY logo ONCY
Upturn stock ratingUpturn stock rating
ONCY logo

Oncolytics Biotech Inc (ONCY)

Upturn stock ratingUpturn stock rating
$1.04
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/29/2025: ONCY (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

6 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $4.63

1 Year Target Price $4.63

Analysts Price Target For last 52 week
$4.63 Target price
52w Low $0.33
Current$1.04
52w High $1.53

Analysis of Past Performance

Type Stock
Historic Profit 29.52%
Avg. Invested days 29
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 3.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/29/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 105.30M USD
Price to earnings Ratio -
1Y Target Price 4.63
Price to earnings Ratio -
1Y Target Price 4.63
Volume (30-day avg) 6
Beta 1.09
52 Weeks Range 0.33 - 1.53
Updated Date 08/30/2025
52 Weeks Range 0.33 - 1.53
Updated Date 08/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.27

Earnings Date

Report Date 2025-08-08
When -
Estimate -0.0885
Actual -0.07

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -74.56%
Return on Equity (TTM) -249.28%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 95305764
Price to Sales(TTM) -
Enterprise Value 95305764
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -1.79
Shares Outstanding 101246000
Shares Floating 98776415
Shares Outstanding 101246000
Shares Floating 98776415
Percent Insiders 3.61
Percent Institutions 1.68

ai summary icon Upturn AI SWOT

Oncolytics Biotech Inc

stock logo

Company Overview

overview logo History and Background

Oncolytics Biotech Inc. was founded in 1998. It's a biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Significant milestones include advancing Reolysin through clinical trials and establishing partnerships for development and commercialization.

business area logo Core Business Areas

  • Reolysin Development: Development of Reolysin, an oncolytic virus, for the treatment of various cancers, including breast cancer, pancreatic cancer and head and neck cancer. The company works towards clinical trials and potential market launch.

leadership logo Leadership and Structure

The leadership team consists of individuals with experience in the biotechnology and pharmaceutical industries. The company is structured around research and development, clinical trials, and corporate management.

Top Products and Market Share

overview logo Key Offerings

  • Reolysin: Reolysin is Oncolytics Biotech Inc.'s primary product, an oncolytic virus being investigated as a cancer therapeutic in clinical trials. Currently, it does not have market share. Competitors include other oncolytic virus developers like Amgen (IMLYGIC), BioVaxys Technology Corp (BIOV.CN), and Replimune (REPL).

Market Dynamics

industry overview logo Industry Overview

The oncolytic virus therapy market is growing, driven by the potential of these viruses to selectively target and destroy cancer cells. There's increasing interest and investment in this field, with several companies developing novel oncolytic virus therapies.

Positioning

Oncolytics Biotech Inc. is positioned as a developer of Reolysin, aiming to demonstrate its efficacy in various cancer types. The company's competitive advantage lies in the potential of Reolysin and it targets specific cancer indications.

Total Addressable Market (TAM)

The oncolytic virus therapy market is projected to reach billions of dollars. Oncolytics' TAM is tied to the specific cancer indications Reolysin targets and how they advance in clinical trials. The TAM for oncolytic virus therapy is projected to be between $700 million and $1 billion by 2028.

Upturn SWOT Analysis

Strengths

  • Proprietary Reolysin technology
  • Clinical trial progress
  • Experienced management team

Weaknesses

  • Limited financial resources
  • Dependence on Reolysin's success
  • Lack of commercialized product

Opportunities

  • Positive clinical trial results
  • Partnerships with pharmaceutical companies
  • Expansion into new cancer indications

Threats

  • Clinical trial failures
  • Competition from other therapies
  • Regulatory hurdles

Competitors and Market Share

competitor logo Key Competitors

  • AMGN
  • REPL
  • VIRI

Competitive Landscape

Oncolytics faces competition from larger pharmaceutical companies with more resources and marketed products. However, Oncolytics' specific focus on Reolysin in targeting specific cancer indications provides a unique competitive edge.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is largely driven by advancements in the clinical trials for Reolysin

Future Projections: Future growth hinges on successful clinical trial outcomes, regulatory approvals, and partnerships.

Recent Initiatives: Recent initiatives include enrolling patients in clinical trials and seeking partnerships for further development of Reolysin.

Summary

Oncolytics Biotech is in early stages with strong potential but requires more time for development. Its main strength lies in Reolysin, but its financial situation and the success of clinical trials are crucial to watch. Positive clinical trial results and partnerships could drive significant growth, while regulatory hurdles and competition pose ongoing threats.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • SEC Filings
  • Market Research Reports
  • Analyst Reports

Disclaimers:

The information provided is for informational purposes only and does not constitute financial advice. Market share estimates are approximate. The AI rating is generated based on currently available data and is subject to change.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Oncolytics Biotech Inc

Exchange NASDAQ
Headquaters Calgary, AB, Canada
IPO Launch date 1999-11-08
CEO & Director Mr. Jared Kelly J.D., L.L.M.
Sector Healthcare
Industry Biotechnology
Full time employees 28
Full time employees 28

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.